Board Profiles


Mr Thian Chew

Chair

Mr Chew has over 25 years' experience in investing, finance and transforming business operations. He is currently Managing Partner at Polar Ventures, a private investment and consulting firm that provides capital, strategic and operating solutions, focusing on small to mid-sized enterprises in Asia.

Mr Chew was previously an Executive Director at Goldman Sachs (Hong Kong and New York), responsible for the firm's proprietary investments, including growth capital, private equity and special situations. Other previous roles include Consultant Project Manager to Morgan Stanley and a number of positions at KPMG across the Asia-Pacific region, including Director at KPMG Consulting (Singapore and Sydney).

Mr Chew holds an MBA from the Wharton School (Palmer Scholar); an MA from the Lauder Institute, University of Pennsylvania; and a Bachelor of Information Systems from Monash University. Mr Chew is an Adjunct Professor at HKUST's MBA program and previously qualified as a chartered accountant.





Greg Collier PhD

Managing Director and Chief Executive Officer

Dr Collier has more than 25 years' experience spanning operational, clinical and scientific aspects of pharmaceutical research, development and commercialisation. He has led the planning and execution of multiple commercial transactions, including licensing deals, major M&A activities, and has successfully taken a drug from discovery through to regulatory approval.

Notably, Dr Collier steered ChemGenex Pharmaceuticals from a research-based company with a market capitalisation of $10 million to a company with completed clinical trials and regulatory dossiers submitted to the FDA and EMA.

In 2011, Cephalon acquired ChemGenex for $230 million. Prior to his commercial pharmaceutical career, Dr Collier had an outstanding academic career, highlighted by over 150 peer-reviewed publications and senior authorship on 33 patents. Dr Collier was the inaugural Alfred Deakin Professor at Deakin University and held positions at Melbourne University, Monash University and University of Toronto. In 2010, Dr Collier was awarded the Roche Award of Excellence for his contribution to the biotechnology industry.





James Campbell PhD MBA

Non-Executive Director

Dr Campbell has more than 25 years of international biotechnology research, management and leadership experience and has been involved in the creation and/or transformation of multiple successful Australian and international biotechnology companies.

Dr Campbell was previously the CFO and COO of ChemGenex Pharmaceuticals Ltd (ASX: CXS), where, as a member of the executive team, he helped transform a research-based company with a market capitalisation of $10 million to a company with completed clinical trials and regulatory dossiers submitted to the FDA and EMA. In 2011, ChemGenex was sold to Cephalon for $230 million.

Dr Campbell currently sits on the Advisory Board of Deakin University’s Centre for Innovation in Mental and Physical Health and Clinical Treatment (IMPACT), along with other current roles that include Managing Director & CEO of Patrys Ltd (ASX: PAB) and Non-Executive Director of Prescient Therapeutics Ltd (ASX: PTX).





Alan Yamashita

Director

Mr Yamashita is a highly experienced corporate consultant and investment professional, with over 40 years' experience in investment management, investment banking and alternative investment throughout the APAC region.

From 1999 to 2005, Mr Yamashita was President and CEO of Search Investment Group and founding CEO and CIO of Search Alternative Investment Ltd (SAIL), a major private global hedge fund and private equity investment practice headquartered in Asia.

Prior to Search Investments Group, Mr Yamashita was Managing Director and Head of Asia Capital Markets for Merrill Lynch from 1996 to 1998.

Mr Yamashita is currently Managing Partner at Polar Ventures and has held numerous positions as a 16-year veteran of Goldman Sachs and an advisor to various companies, including Plantation Timber Partners, Wuhan; Duty Free Shoppers, Asia; TVSN, Shanghai; and Mizuho Alternative Investments LLC.